EHB is committed to discover and to develop new natural-derived molecules targeting the endocannabinoid system for the treatment of chronic inflammatory and neurodegenerative diseases.
EHB has developed a sequential platform of primary and secondary screenings that are able to analyze more than 30 key molecular targets in inflammation and cancer pathways, including the endocannabinoid system.
We are experts in screening of hit compounds, identification of mechanism of action and assessment of the efficacy of molecules and phytoextracts for pharmaceutical, nutraceutical and cosmetic uses.